Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Oct 08, 2026
TickeronGET DAILY SIGNALS
Why Is Glaukos Corporation (GKOS) Stock Down -11.58% Today?

Why Is Glaukos Corporation (GKOS) Stock Down -11.58% Today?

Key Takeaways

  • GKOS shares fell roughly 11.58% intraday, giving back a large portion of the previous session's surge.
  • The decline followed a steep rally, pointing to profit-taking and a "sell-the-news" response rather than a negative fundamental development.
  • The company announced a first-in-class retinal licensing deal with RevOpsis Therapeutics, but undisclosed financial terms left some investors cautious.
  • The stock had more than doubled off its 52-week low and gained over 67% year to date, leaving it vulnerable to sharp pullbacks.
  • Traders are watching third-quarter earnings, due after the close on October 28, as the next major catalyst.

Opening Summary

Glaukos Corporation (GKOS), an ophthalmic pharmaceutical and medical technology company known for its Micro-Invasive Glaucoma Surgery (MIGS) platform, the iDose TR implant, and the Epioxa corneal cross-linking therapy, is trading sharply lower on Thursday. The stock was down about 11.58% to roughly $152.24, compared with a prior-session close of $172.18. The reversal comes just one day after shares jumped 6.55% on positive long-term Epioxa data, highlighting how quickly momentum-driven gains can unwind in a high-flying growth name.

Profit-Taking After a Steep Rally

The most immediate driver behind today's slide appears to be profit-taking rather than any deterioration in the company's underlying business. GKOS entered the session with substantial gains already banked: the stock had climbed more than 67% year to date and had more than doubled from its 52-week low, dramatically outperforming both the broader market and the medical-device sector. After such a run, a single-day pullback of this magnitude often reflects investors locking in gains, particularly when a stock has run ahead of near-term fundamentals.

Valuation concerns reinforced the selling pressure. At the start of the week, shares traded at a premium that some analysts characterized as rich relative to the company's still-negative earnings profile, with Glaukos continuing to report net losses even as revenue grows rapidly. When a high-multiple growth stock reverses, the move can be amplified by momentum traders and algorithmic selling.

A "Sell-the-News" Response to the RevOpsis Deal

Compounding the unwind, Glaukos announced on Thursday morning an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104, a first-in-class tri-specific biologic targeting VEGF-A, VEGF-C, and Ang-2 for retinal diseases including wet age-related macular degeneration (nAMD) and diabetic macular edema. The deal also grants rights to RevOpsis's RevMod platform for up to four additional candidates.

While the announcement was strategically positive, expanding Glaukos's retinal pipeline, markets reacted with a classic "buy the rumor, sell the news" pattern. Crucially, financial terms of the agreement were not disclosed, leaving investors unable to assess the near-term cash or dilution impact. With the stock already up sharply, the lack of visibility on deal economics gave traders an excuse to take profits rather than chase the news higher.

Market Context and Trading Activity

Trading in GKOS was heavy, consistent with a high-momentum name unwinding recent gains. The prior session's rally itself came on unusually elevated volume, and Thursday's reversal continued that elevated activity as positions were trimmed. The decline also coincided with relative weakness in the healthcare and medical-device complex, where richly valued growth names have been sensitive to shifting risk appetite.

From a technical standpoint, the drop pushed the stock well below its recent breakout levels and below short-term moving averages, erasing a large portion of Wednesday's advance. Such swift reversals often trigger additional selling as stop-losses are hit and short-term traders exit positions.

What Comes Next for GKOS

The next significant catalyst for GKOS is its third-quarter 2026 earnings report, scheduled for release after the market close on October 28. Investors will focus on iDose TR adoption, early Epioxa launch traction, and any updates to the company's full-year revenue guidance, which management raised to a range of $680 million to $700 million after a strong second quarter.

Key risks include the pace of reimbursement decisions, procedure volume trends, and competition in both the glaucoma and retinal markets. Analysts remain broadly constructive, with a consensus Buy rating, but the stock's recent volatility underscores that even a positive long-term story can experience sharp, sentiment-driven corrections. Investors will be watching whether the pullback stabilizes ahead of earnings or extends as broader market conditions shift.

Trending AI Robots

For traders seeking a systematic edge in fast-moving names like GKOS, Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, giving traders a range of automated approaches to explore. Visit the Trending AI Robots page to see which strategies are currently outperforming.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: GKOS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


GKOS in downward trend: price may decline as a result of having broken its higher Bollinger Band on October 29, 2026

GKOS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 46 similar instances where the stock broke above the upper band. In 34 of the 46 cases the stock fell afterwards. This puts the odds of success at 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for GKOS moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 27 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 71 cases where GKOS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 61%.

The Moving Average Convergence Divergence Histogram (MACD) for GKOS turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In 41 of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GKOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on GKOS as a result. In 82 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.

GKOS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for GKOS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

Following a +8.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where GKOS advanced for three days, in 248 of 316 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

The Aroon Indicator entered an Uptrend today. In 232 of 314 cases where GKOS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 74%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 13 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Seasonality Score of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GKOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (19.395) is normal, around the industry mean (4.142). P/E Ratio (-68.627) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (12.570) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (15.456) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an ophthalmic medical device company

Industry MedicalNursingServices

Industry
Medical Specialties
Address
One Glaukos Way
Phone
+1 949 367-9600
Employees
1094
Web
https://www.glaukos.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.